Mitsubishi Tanabe Pharma America, launched in 2016 as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation, is dedicated to developing innovative treatments for serious and debilitating diseases. The company, based in Jersey City, USA, employs 284 individuals and is committed to driving scientific discovery and innovation. MTPA focuses on creating treatments that improve the lives of patients with unmet medical needs.
The company's mission is centered around scientific discovery and innovation, aiming to bring new treatments to market that address serious health conditions. Mitsubishi Tanabe Pharma America's approach to research and development is comprehensive, ensuring that each treatment is thoroughly tested and meets the highest standards of safety and efficacy.
MTPA's commitment to innovation is evident in its approach to drug development, which includes rigorous clinical trials and a focus on patient outcomes. The company's dedication to improving patient lives is reflected in its strategic partnerships and collaborations with other healthcare organizations.
| Ownership Private Company |
| Parent Company Mitsubishi Tanabe Pharma Corporation |
B2B professionals should contact Mitsubishi Tanabe Pharma America for opportunities in drug development and innovative treatment partnerships. The company's focus on scientific discovery and patient outcomes makes it an ideal partner for those seeking to advance healthcare solutions.
Sales teams selling pharmaceutical products, researchers in drug development, and healthcare organizations interested in innovative treatment partnerships should reach out to Mitsubishi Tanabe Pharma America.
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with Mitsubishi Tanabe Pharma America